Go Pro
→ How options let you do more with less capital (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$41.75
+3.0%		$46.81
$27.00
▼
$55.67
$6.80B0.322.24 million shs2.25 million shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$33.62
-0.1%		$39.16
$15.95
▼
$45.42
$6.95B0.841.50 million shs1.02 million shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$92.83
-0.6%		$105.42
$74.50
▼
$122.20
$6.40B2.01676,387 shs501,086 shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$11.17
-1.1%		$10.19
$4.82
▼
$11.94
$1.91B1.591.96 million shs2.18 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
+0.05%-0.61%-14.11%-25.72%+32.27%
Immunovant, Inc. stock logo
IMVT
Immunovant
-0.38%-1.03%-15.66%-13.25%+105.94%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-1.89%-4.98%-10.82%-18.18%-6.60%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
+0.98%+5.32%-2.92%+12.45%+98.07%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$41.75
+3.0%		$46.81
$27.00
▼
$55.67
$6.80B0.322.24 million shs2.25 million shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$33.62
-0.1%		$39.16
$15.95
▼
$45.42
$6.95B0.841.50 million shs1.02 million shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$92.83
-0.6%		$105.42
$74.50
▼
$122.20
$6.40B2.01676,387 shs501,086 shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$11.17
-1.1%		$10.19
$4.82
▼
$11.94
$1.91B1.591.96 million shs2.18 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
+0.05%-0.61%-14.11%-25.72%+32.27%
Immunovant, Inc. stock logo
IMVT
Immunovant
-0.38%-1.03%-15.66%-13.25%+105.94%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-1.89%-4.98%-10.82%-18.18%-6.60%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
+0.98%+5.32%-2.92%+12.45%+98.07%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alkermes plc stock logo
ALKS
Alkermes
2.74
Moderate Buy$54.4730.47% Upside
Immunovant, Inc. stock logo
IMVT
Immunovant
2.58
Moderate Buy$44.0030.87% Upside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
2.76
Moderate Buy$140.6751.53% Upside
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.88
Moderate Buy$21.5793.12% Upside

Current Analyst Ratings Breakdown

Latest VIR, IMVT, ALKS, and RYTM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/28/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingStrong-Buy
9/24/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/24/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingPositive
9/24/2026
Alkermes plc stock logo
ALKS
Alkermes
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$50.00
9/24/2026
Alkermes plc stock logo
ALKS
Alkermes
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold$50.00
9/23/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/22/2026
Alkermes plc stock logo
ALKS
Alkermes
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$56.00
9/22/2026
Alkermes plc stock logo
ALKS
Alkermes
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$58.00 ➝ $61.00
9/21/2026
Alkermes plc stock logo
ALKS
Alkermes
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/21/2026
Alkermes plc stock logo
ALKS
Alkermes
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/21/2026
Alkermes plc stock logo
ALKS
Alkermes
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$62.00
(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alkermes plc stock logo
ALKS
Alkermes
$1.48B4.75$1.72 per share24.21$11.02 per share3.79
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$4.19 per shareN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$239.92M26.52N/AN/A$2.08 per share44.63
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$68.56M27.57N/AN/A$5.50 per share2.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alkermes plc stock logo
ALKS
Alkermes
$241.66M$0.38109.87173.96N/A3.96%4.15%2.19%10/28/2026 (Estimated)
Immunovant, Inc. stock logo
IMVT
Immunovant
-$505.61M-$2.82N/AN/AN/AN/A-69.59%-62.49%11/9/2026 (Estimated)
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$196.54M-$3.11N/AN/AN/A-85.59%-159.87%-44.00%11/3/2026 (Estimated)
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$437.99M-$1.86N/AN/AN/AN/A-29.99%-23.62%11/4/2026 (Estimated)

Latest VIR, IMVT, ALKS, and RYTM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/28/2026Q3 2026
Alkermes plc stock logo
ALKS
Alkermes
-$0.0781N/AN/AN/A$463.47 millionN/A
8/6/2026Q1 2027
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.6289-$0.75-$0.1211-$0.75$7.10 million$7.10 million
8/5/2026Q2 2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$0.3326$0.47+$0.1374$0.47$135.88 million$238.95 million
8/4/2026Q2 2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.8072-$0.73+$0.0772-$0.73$67.66 million$71.26 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alkermes plc stock logo
ALKS
Alkermes
0.82
2.30
1.85
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
7.27
7.27
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
3.45
3.20
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/A
6.04
6.04

Institutional Ownership

CompanyInstitutional Ownership
Alkermes plc stock logo
ALKS
Alkermes
95.21%
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
65.32%

Insider Ownership

CompanyInsider Ownership
Alkermes plc stock logo
ALKS
Alkermes
4.59%
Immunovant, Inc. stock logo
IMVT
Immunovant
1.90%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
5.90%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alkermes plc stock logo
ALKS
Alkermes
2,050167.76 million160.06 millionOptionable
Immunovant, Inc. stock logo
IMVT
Immunovant
315206.55 million202.63 millionOptionable
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
41468.53 million64.49 millionOptionable
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
367169.22 million164.31 millionOptionable

Recent News About These Companies

Vir Biotechnology Names Aziz Sawaf as CFO
October 1 at 5:53 PM  |  marketscreener.comM
Vir Biotechnology Names Aziz Sawaf Chief Financial Officer
October 1 at 5:53 PM  |  marketwatch.comhttps://www.marketwatch.com/story/vir-biotechnology-names-aziz-sawaf-chief-financial-officer-9e5a7492
Vir Biotechnology, Inc. Announces Executive Changes
October 1 at 5:53 PM  |  marketscreener.comM
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
October 1 at 5:53 PM  |  biospace.comB
Vir Biotechnology Appoints Aziz Sawaf As CFO
October 1 at 5:53 PM  |  pulse2.comP
Raymond James reiterates USD 19.00 target for Vir Biotechnology stock
October 1 at 7:52 AM  |  ad-hoc-news.deA
Vir Biotechnology, Inc. (VIR) Stock Earnings Call Transcripts - Yahoo Finance
September 30 at 10:19 AM  |  finance.yahoo.comhttps://finance.yahoo.com/quote/VIR/earnings-calls/
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
September 30 at 4:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068155
Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Rated "Moderate Buy" by Sell-Side Brokerages
September 30 at 4:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-vir-biotechnology-inc-nasdaq-vir-stock-rated-moderate-buy-by-sell-side-brokerages-2026-09-30/
Vir Biotechnology: Astellas Deal Highlights The Platform's Value
September 29 at 7:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4950588-vir-biotechnology-astellas-deal-highlights-the-platforms-value
Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir
September 28, 2026  |  fiercebiotech.comF
GeoVax Labs (NASDAQ:GOVX) & Vir Biotechnology (NASDAQ:VIR) Head to Head Contrast
September 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31054980
Can Vir Biotechnology (NASDAQ:VIR) deliver on its packed clinical calendar?
September 26, 2026  |  kalkinemedia.comK
Bank of America Corp DE Acquires 1,142,539 Shares of Vir Biotechnology, Inc. $VIR
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-acquires-1142539-shares-of-vir-biotechnology-inc-vir-2026-09-26/
Vir Biotechnology stock falls 3.34 percent after Q2 results
September 25, 2026  |  ad-hoc-news.deA
Engineers Gate Manager LP Sells 121,964 Shares of Vir Biotechnology, Inc. $VIR
September 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-engineers-gate-manager-lp-sells-121964-shares-of-vir-biotechnology-inc-vir-2026-09-18/
Vir Biotechnology, Inc. $VIR Shares Acquired by Squarepoint Ops LLC
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vir-biotechnology-inc-vir-shares-acquired-by-squarepoint-ops-llc-2026-09-17/
WINTON GROUP Ltd Trims Stake in Vir Biotechnology, Inc. $VIR
September 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-winton-group-ltd-trims-stake-in-vir-biotechnology-inc-vir-2026-09-13/
Legal & General Group Plc Invests $2.76 Million in Vir Biotechnology, Inc. $VIR
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-invests-276-million-in-vir-biotechnology-inc-vir-2026-09-06/
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Brokerages
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-vir-biotechnology-inc-nasdaq-vir-given-consensus-rating-of-moderate-buy-by-brokerages-2026-09-05/
Bank of New York Mellon Corp Makes New $7.08 Million Investment in Vir Biotechnology, Inc. $VIR
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-makes-new-708-million-investment-in-vir-biotechnology-inc-vir-2026-09-04/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Close-up of a carbon fiber surface bearing the AV logo and a camera sensor.
AeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone Opportunity
By Ryan Hasson | September 3, 2026
Autonomous military drone with AV-style logo on the nose sitting on a runway, representing AeroVironment and the defense drone industry.
AeroVironment's Record Backlog and Earnings Beat Fuel Recovery Case
By Thomas Hughes | September 10, 2026
Three military surveillance drones fly near a mobile radar unit at an airfield during sunset.
3 Defense Stocks Riding the High-Energy Laser Boom
By Nathan Reiff | September 15, 2026
Curaleaf logo illuminated on a lobby wall, with cannabis plants visible through windows in the background.
Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
By Jeffrey Neal Johnson | September 15, 2026
Intel logo displayed on a computer chip embedded in an illuminated blue circuit board.
Intel's Ohio Lifeline? Why the SK Hynix Talks Matter
By Chris Markoch | September 18, 2026
Alkermes stock logo

Alkermes NASDAQ:ALKS

$41.75 +1.21 (+2.98%)
Closing price 04:00 PM Eastern
Extended Trading
$41.64 -0.10 (-0.25%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$33.62 -0.03 (-0.09%)
Closing price 04:00 PM Eastern
Extended Trading
$33.63 +0.01 (+0.03%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Rhythm Pharmaceuticals stock logo

Rhythm Pharmaceuticals NASDAQ:RYTM

$92.83 -0.58 (-0.62%)
Closing price 04:00 PM Eastern
Extended Trading
$92.82 0.00 (-0.01%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Vir Biotechnology stock logo

Vir Biotechnology NASDAQ:VIR

$11.17 -0.12 (-1.06%)
Closing price 04:00 PM Eastern
Extended Trading
$11.00 -0.17 (-1.52%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas